Amiodarone-Induced Thyrotoxicosis in a Patient with Autonomously Functioning Nodular Goiter (original) (raw)

Abstract

A miodarone is an effective antiarrhythmic agent for treatment and prophylaxis of life-threatening ventricular arrhythmias. It contains 37% organic iodine in its molecular mass, or about 75 mg of iodine per 200-mg tablet, 10% of which is released as unbound iodide. 1 A dosage of 200 mg of amiodarone daily provides roughly 50 times the recommended iodine requirement determined by the World Health Organization (150 µg/day for adults). 2-4 Amiodarone is also highly lipophilic and accumulates in adipose tissue after ingestion, leading to its long elimination half-life (~100 days). 3,5 This "iodine-rich" characteristic is believed to be the major etiology of amiodarone-induced thyroid dysfunction, which includes failure to escape from the Wolff-Chaikoff effect, iodine-induced potentiation of thyroid autoimmunity, and unregulated hormone synthesis (Jod-Basedow effect). In addition, amiodarone inhibits type 1 5'-deiodinase activity, thereby decreasing the peripheral conversion of thyroxine (T 4 ) to triiodothyronine (T 3 ) and the clearance of both T 4 and reverse T 3 . Amiodarone can act as a competitive antagonist of T 3 and inhibit the entry of thyroid hormones into peripheral tissues. Cytotoxic effects that cause lysis of thyroid follicles have also been described. 1,3, Adverse reactions to amiodarone are complex and include amiodarone-induced thyrotoxicosis (AIT) and hy-pothyroidism (AIH). In iodine-sufficient geographic areas, AIT is less common than AIH. 1,7 Although the overall incidence of thyroid dysfunction by amiodarone is about 2-24%, 3,8 AIT should be considered in patients taking amiodarone who develop symptoms and signs of thyrotoxicosis including weight loss, tremors, restlessness, and tachycardia. Laboratory tests usually demonstrate depressed thyroid-stimulating (TSH) levels with elevated T 4 and T 3 levels. AIT is further classified as type 1 or type 2 based on different etiologies. Type 1 AIT is due to unregulated hor-Author information provided at the end of the text.

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.

References (26)

  1. Cardenas GA, Cabral JM, Leslie CA. Amiodarone induced thyrotoxico- sis: diagnostic and therapeutic strategies. Cleve Clin J Med 2003;70:624- 31.
  2. Fradkin JE, Wolff J. Iodide-induced thyrotoxicosis. Medicine (Balti- more) 1983;62:1-20.
  3. Martino E, Bartalena L, Bogazzi F, Braverman LE. The effects of amiodarone on the thyroid. Endocr Rev 2001;22:240-54.
  4. Vitamin and mineral requirements in human nutrition. 2nd ed. World Health Organization and Food and Agriculture Organization, 2004.
  5. Bogazzi F, Bartalena L, Gasperi M, Braverman LE, Martino E. The various effects of amiodarone on thyroid function. Thyroid 2001;11:511-9.
  6. Basaria S, Cooper DS. Amiodarone and the thyroid. Am J Med 2005; 118:706-14.
  7. Martino E, Safran M, Aghini-Lombardi F, et al. Environmental iodine intake and thyroid dysfunction during chronic amiodarone therapy. Ann Intern Med 1984;101:28-34.
  8. Harjai KJ, Licata AA. Effects of amiodarone on thyroid function. Ann Intern Med 1997;126:63-73.
  9. Charkes ND, Polin EB. Propranolol-induced hyperthyroxinemia in a pa- tient with an autonomous thyroid nodule. J Fam Pract 1987;25:171-3.
  10. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the prob- ability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
  11. Daniels GH. Amiodarone-induced thyrotoxicosis. J Clin Endocrinol Metab 2001;86:3-8.
  12. Brian SR, Cheng DW, Goldberg PA. Unusual case of amiodarone-in- duced thyrotoxicosis: "illicit" use of a technetium scan to diagnose a transiently toxic thyroid nodule. Endocr Pract 2007;13:413-6.
  13. Pearce EN, Bogazzi F, Martino E, et al. The prevalence of elevated serum C-reactive protein levels in inflammatory and noninflammatory thyroid disease. Thyroid 2003;13:643-8.
  14. Macedo TA, Chammas MC, Jorge PT, et al. Differentiation between the two types of amiodarone-associated thyrotoxicosis using duplex and am- plitude Doppler sonography. Acta Radiol 2007;48:412-21.
  15. Loy M, Perra E, Melis A, et al. Color-flow Doppler sonography in the differential diagnosis and management of amiodarone-induced thyrotox- icosis. Acta Radiol 2007;48:628-34.
  16. Bogazzi F, Bartalena L, Brogioni S, et al. Color flow Doppler sonogra- phy rapidly differentiates type I and type II amiodarone-induced thyro- toxicosis. Thyroid 1997;7:541-5.
  17. Trip MD, Wiersinga W, Plomp TA. Incidence, predictability, and patho- genesis of amiodarone-induced thyrotoxicosis and hypothyroidism. Am J Med 1991;91:507-11.
  18. Mariotti S, Loviselli A, Murenu S, et al. High prevalence of thyroid dys- function in adult patients with beta-thalassemia major submitted to amio- darone treatment. J Endocrinol Invest 1999;22:55-63.
  19. Thorne SA, Barnes I, Cullinan P, Somerville J. Amiodarone-associated thyroid dysfunction: risk factors in adults with congenital heart disease. Circulation 1999;100:149-54.
  20. Monteiro E, Galvao-teles A, Santos ML, et al. Antithyroid antibodies as an early marker for thyroid disease induced by amiodarone. Br Med J (Clin Res Ed) 1986;292:227-8.
  21. Sato K, Yamazaki K, Kanaji Y, Ohnishi S, Kasanuki H, Demura H. Amiodarone-induced thyrotoxicosis associated with thyrotropin receptor antibody. Thyroid 1998;8:1123-6.
  22. Rajeswaran C, Shelton RJ, Gilbey SG. Management of amiodarone-in- duced thyrotoxicosis. Swiss Med Wkly 2003;133:579-85.
  23. Tanda ML, Piantanida E, Lai A, et al. Diagnosis and management of amiodarone-induced thyrotoxicosis: similarities and differences between North American and European thyroidologists. Clin Endocrinol (Oxf) 2008;69:812-8. Epub 16 Apr 2008.
  24. Boeving A, Cubas ER, Santos CM, Carvalho GA, Graf H. [Use of lithi- um carbonate for the treatment of amiodarone-induced thyrotoxicosis] Portuguese. Arq Bras Endocrinol Metabol 2005;49:991-5.
  25. Monzani F, Del Guerra P, Caraccio N, Casolaro A, Pucci E, Franchi F. Percutaneous ethanol injection therapy of autonomous nodule and amio- darone-induced thyrotoxicosis. Thyroidology 1994;6:99-102.
  26. Smyrk TC, Goellner JR, Brennan MD, Carney JA. Pathology of the thy- roid in amiodarone-associated thyrotoxicosis. Am J Surg Pathol 1987; 11:197-204.